A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

NCT03656536 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

167

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.

Conditions

Unresectable Cholangiocarcinoma
Metastatic Cholangiocarcinoma

Interventions

DRUG: Pemigatinib
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Incyte Corporation